William Shakespeare - 06 Nov 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.

Role
President of Research and Development
Signature
/s/ Bradford Dahms - Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
06 Nov 2023
Net transactions value
+$80,347
Form type
4
Filing time
07 Nov 2023, 16:03:37 UTC
Previous filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction THRX Common Stock Options Exercise $80,347 +251,084 +65% $0.3200* 639,408 06 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction THRX Stock Option (right to buy) Options Exercise $0 -251,084 -73% $0.000000 93,260 06 Nov 2023 Common Stock 251,084 $0.3200 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options are immediately exercisable in full due to early exercise rights, subject to the issuer's right of repurchase. The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 18, 2020, subject to the Reporting Person's continuous service with the issuer.

Remarks:

President of Research and Development